DK1268387T3 - Specifikke saltformer af triphenylethylenderivater som selektive östrogenreceptormodulatorer - Google Patents

Specifikke saltformer af triphenylethylenderivater som selektive östrogenreceptormodulatorer

Info

Publication number
DK1268387T3
DK1268387T3 DK01926670T DK01926670T DK1268387T3 DK 1268387 T3 DK1268387 T3 DK 1268387T3 DK 01926670 T DK01926670 T DK 01926670T DK 01926670 T DK01926670 T DK 01926670T DK 1268387 T3 DK1268387 T3 DK 1268387T3
Authority
DK
Denmark
Prior art keywords
estrogen receptor
salt forms
receptor modulators
selective estrogen
specific salt
Prior art date
Application number
DK01926670T
Other languages
Danish (da)
English (en)
Inventor
Gary A Cain
Reginald O Cann
Christopher A Teleha
Denette K Murphy
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of DK1268387T3 publication Critical patent/DK1268387T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK01926670T 2000-04-05 2001-04-05 Specifikke saltformer af triphenylethylenderivater som selektive östrogenreceptormodulatorer DK1268387T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19458000P 2000-04-05 2000-04-05
PCT/US2001/011169 WO2001077055A2 (en) 2000-04-05 2001-04-05 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
DK1268387T3 true DK1268387T3 (da) 2004-10-18

Family

ID=22718126

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01926670T DK1268387T3 (da) 2000-04-05 2001-04-05 Specifikke saltformer af triphenylethylenderivater som selektive östrogenreceptormodulatorer

Country Status (12)

Country Link
US (1) US6417394B2 (de)
EP (1) EP1268387B1 (de)
JP (1) JP2004507452A (de)
AT (1) ATE269291T1 (de)
AU (2) AU2001253191B2 (de)
CA (1) CA2403263A1 (de)
DE (1) DE60103867T2 (de)
DK (1) DK1268387T3 (de)
ES (1) ES2222988T3 (de)
PT (1) PT1268387E (de)
TR (1) TR200401601T4 (de)
WO (1) WO2001077055A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002323098A1 (en) 2001-08-11 2003-03-03 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
EP1692127B1 (de) 2003-10-08 2008-07-02 Smithkline Beecham Corporation Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
US7196119B2 (en) * 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
US7425580B2 (en) * 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
US20080234199A1 (en) * 2005-11-22 2008-09-25 Smithkline Beecham Corporation Chemical Compounds
WO2009120999A2 (en) * 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
EP2802608A4 (de) * 2012-01-12 2015-08-05 Univ Yale Verbindungen und verfahren für den verstärkten abbau von gezielten proteinen und anderen polypeptiden durch eine e3-ubiquitinligase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
HUP0002852A3 (en) * 1997-08-15 2001-11-28 Univ Durham A method of preventing or treating estrogen-dependent diseases and disorders using triphenil-ethylene derivatives

Also Published As

Publication number Publication date
EP1268387B1 (de) 2004-06-16
ATE269291T1 (de) 2004-07-15
JP2004507452A (ja) 2004-03-11
CA2403263A1 (en) 2001-10-18
DE60103867D1 (de) 2004-07-22
WO2001077055A3 (en) 2002-05-30
PT1268387E (pt) 2004-09-30
US20020004496A1 (en) 2002-01-10
ES2222988T3 (es) 2005-02-16
US6417394B2 (en) 2002-07-09
EP1268387A2 (de) 2003-01-02
TR200401601T4 (tr) 2004-08-23
AU2001253191B2 (en) 2006-03-02
WO2001077055A2 (en) 2001-10-18
AU5319101A (en) 2001-10-23
DE60103867T2 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
DK1353672T3 (da) Syntese af 4-amino-thalidomidenantiomerer
AU2001231710A1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
WO2003016270A3 (en) Selective estrogen receptor modulators
NO20031687D0 (no) Veksthormonsekretagoger
WO2006126939A8 (en) Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
DK1436257T3 (da) Oxim-analogica af 1-alpha, 25-dihydroxy-vitamin-D3 med ringe kalcemisk virkning
CY1109989T1 (el) 3,4-di-υποκαθισταμενες cyclobutene-1,2-diones ως συνδετες του υποδοχεα των cxc-χημειοκινων
DE69935335D1 (de) Pyrazole als modulatoren des östrogenrezeptors
NO990066D0 (no) Apoptose-induserende adamantylderivater og deres anvendelse som anticancer-midler
SE0302232D0 (sv) Novel Compounds
SE0302760D0 (sv) New compounds
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
DE60038953D1 (de) Zusammensetzung enthaltend MX-DTPA und dessen Verwendung zur Herstellung von radiomarkiertem MX-DTPA
DK1268387T3 (da) Specifikke saltformer af triphenylethylenderivater som selektive östrogenreceptormodulatorer
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
MEP23008A (en) Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
DE60105785D1 (de) Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren
MXPA01008347A (es) Compuestos quimicos.
PL376896A1 (pl) Sposoby wytwarzania 5-androstenów podstawionych w pozycji C-7
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
GB0425548D0 (en) Radiolabelled ligands
TNSN03090A1 (fr) Derives d'ethers phenyliques d'heterocyclyle servant d' inhibiteurs selectifs de reabsorption de serotonine
RS56004A (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
WO2004087673A3 (en) Migrastatin analogs and uses thereof